A look at the treatment landscape of advanced prostate cancer.

Ascenta Therapeutics announced positive preliminary results from its Phase II study of AT-101 in combination with docetaxel and prednisone (D/P) in men with docetaxel refractory, castrate resistant prostate cancer (CRPC) at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, FL.

LINTHICUM, Md., Feb. 27 (UPI) — Healthy men screened regularly for prostate cancer who show no symptoms should talk with doctors about a drug, new U.S. guidelines advise.

An experimental pill that blocks the production of male hormones that fuel prostate cancer may help slow the growth of hard-to-treat tumors.

( University of Illinois at Chicago ) Researchers at the University of Illinois at Chicago’s Institute for Health Research and Policy have been awarded a five-year, $3 million grant from the National Cancer Institute to study the link between body fat and prostate cancer progression.

ANN ARBOR, Mich. — Researchers from the University of Michigan Comprehensive Cancer Center have identified a panel of small molecules, or metabolites, that appear to indicate aggressive prostate cancer.

Following surgery and radiation treatments for prostate cancer, most men suffer some degree of incontinence. For approximately 14 percent of these men, the problem lingers five years later.

For the first time, leading medical groups are advising millions of healthy men who are regularly screened for prostate cancer to consider taking a drug to prevent the disease.

( Case Western Reserve University ) Improving the lives of men with incontinence after prostate surgery is the goal of a new “Stay Dry” intervention being tested by Amy Zhang, assistant professor of nursing at the Frances Payne Bolton School of Nursing at Case Western Reserve University, and colleagues from University Hospitals Case Medical Center, Cleveland Clinic and the Louis Stokes Cleveland …

The FDA says an ad for Glaxo’s prostate drug Avodart makes false statements